Genomics and Interventional Oncology in Metastatic Liver Cancer
Abstract
This review aims to investigate the current literature on genetic and genomic biomarkers of locoregional interventions on metastatic liver metastases. A brief overview on the most common cancers that metastasize to the liver and the role locoregional therapies, such as ablation, chemoembolization, and radioembolization, play in their treatment will be presented. Review of the literature on the genetic, metabolic, and other molecular biomarkers and how they relate to posttreatment survival and outcomes will be discussed. Evaluation of how the existing data can better inform decisions regarding locoregional treatments in those patients with metastatic lesions of the liver will be completed. Personalized treatment paradigms in different types of metastatic cancer present significant opportunities for improved overall clinical outcomes. Optimizing patient selection for localized treatments is vital to improving outcomes and determining which biomarkers correlate with improved efficacy presents many avenues for future research.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 25, 2020
- Source ID
- 10.1055/s-0040-1712120
Entities
People
- Hyun S Kim
- Meaghan Dendy Case
- Ryan Slovak
Organizations
- United States Department of Defense
- University of Connecticut
- Yale Cancer Center
- Yale School of Medicine